Author + information
- Received June 19, 1992
- Revision received October 5, 1992
- Accepted December 1, 1992
- Published online June 1, 1993.
- Steven Borzak, MD, FACC,
- Terence Fenton, EdD,
- Stephen P Glasser, MD, FACC,
- Thomas L Shook, MD, FACC,
- Gail MacCallum, BS,
- Phillip M Young, PharmD,
- Peter H Stone, MD, FACC∗,
- for the Angina and Silent Ischemia Study Group (ASIS)1
- ↵∗Address for correspondence: Peter H. Stone, MD. Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115.
Objectives. We sought to define the extent to which the therapeutic efficacy of three single-drug regimens on ambulatory ischemia paralleled efficacy on other clinical manifestations of ischemia, specifically exercise test performance and anginal symptoms.
Background. Some studies have shown that the presence and severity of ambulatory ischemia are predictive of anginal symptoms and exercise test performance, whereas other studies have not. Less is known about effects of antianginal treatment and whether response to therapy for one clinical manifestation reflects therapeutic responses for other clinical manifestations.
Methods. We studied 50 patients in the Angina and Silent Ischemia Study who had documented coronary disease, an exercise test positive for ischemia, the presence of ambulatory and asymptomatic ischemia on ambulatory electrocardiographic (ECG) Holter monitoring and stable anginal symptoms. Patients received maximally tolerated dose of sustained release propranolol (mean 293 mg/day), sustained release diltiazem (mean 350 mg/day), nifedipine (mean 79 mg/day) and placebo, each for 2-week periods in a double-blind, crossover fashion. Patients' responses to treatment were assessed by 48-h ambulatory ECG monitoring, exercise test (standard Bruce protocol) and diaries of angina. Levels of efficacy for each agent and for each clinical measure were compared using Spearman correlation analysis.
Results. With placebo there was no correlation among the frequency of ischemic episodes by ambulatory ECG monitoring, exercise time to 1.0-mm ST segment depression or frequency of anginal episodes. Furthermore, for a given patient the efficacy of each active medication in reducing ambulatory ischemia was not correlated with response in anginal symptoms or exercise test performance (r = -0.21 to 0.24, p = NS). Within each of these clinical measures, efficacy of one drug was more strongly correlated with efficacy of another drug (r = 0.64 to 0.81 for ambulatory ischemia, 0.48 to 0.56 for exercise test performance and 0.16 to 0.54 for anginal symptoms).
Conclusions. Different measures of ischemia, specifically ambulatory ischemia assessed by ambulatory ECG monitoring, exercise performance on exercise test and anginal symptoms, are independent. Efficacy for each clinical end point must be assessed separately when considering response to drug treatment.
↵1 And participating institutions of the ASIS Sludy Group (see Appendix for personnel and institutions).
☆ This study was supported in part by a grant from Marion-Merrell Dow Incorporated and by a National Research Service Award (TS2-HL 07604) from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
- Received June 19, 1992.
- Revision received October 5, 1992.
- Accepted December 1, 1992.